Share

January 20, 2015; 84 (3) Editorial

Ataxin-2 expands insight into the ALS clinical spectrum

Nancy M. Bonini, Orla Hardiman
First published December 19, 2014, DOI: https://doi.org/10.1212/WNL.0000000000001167
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
181

Share

Article Information

vol. 84 no. 3 224-225
DOI: 
https://doi.org/10.1212/WNL.0000000000001167
PubMed: 
25527266
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Print ISSN: 
0028-3878
Online ISSN: 
1526-632X
History: 
  • First Published December 19, 2014.

Article Versions

Copyright & Usage: 
© 2014 American Academy of Neurology

Author Disclosures

    1. Nancy M. Bonini, PhD and
    2. Orla Hardiman, MD
  1. Nancy M. Bonini, PhD and
    2. Scientific Advisory Boards:

    1. (1) Telethon, Scientific Review Board, 2012- (2) Project ALS, Scientific Review Board, 2012-

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. Annual Reviews of Genetics, Associate Editor, 2005-

    Patents:

    1. (1) US patent Application No 12/965,618, July 2011, UPenn Docket No W5390US, Compositions and methods for the diagnosis and treatment of Amyotrophic Lateral Sclerosis (2) US patent Application/not being pursued NO. 61/547,594, Oct 2012, UPenn Y6028. Trimmer-mediated microRNA processing (3) Disclosure Reference Y6128, Dec 2011 Novel fly wing model for acute neural injury. (4) Disclosure Reference X5985, June 2011, miR-34 modulation with anti-aging and anti-neurodegenerative therapeutic applications

    Publishing Royalties:

    1. (1) Henry Stewart Talk, Royalty, 2008 “Human neurodegenerative disease: insights from Drosophila”

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. (1) NIH, R01-NS066312, Principle Investigator, 2009-2014 (2) NIH, R01-NS073660, Principle Investigator, 2011-2016 (3) NIH, R01-NS078283, Principle Investigator, 2012-2017 (4) NIH, R21-NS088370, Principle Investigator, 2014-2016

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. (1) Howard Hughes Medical Institute, 2000-2013 (2) Ellison Medical Foundation, 2010-2014 (3) Muscular Dystrophy Society, 2009-2012

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. (1) Chimaeric gene coding for a transit peptide and a heterologous polypeptide, patent through Rockefeller University, original application 1985, this application filed 1995 (to my husband, Anthony R. Cashmore).

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Orla Hardiman, MD
    3. Scientific Advisory Boards:

    1. Served on ad hoc advisory boards for Novartis (2010) and Biogen Idec (2010,2012)Allergan (2010), Cytokinetics (2012) Serve on NINDS CDE Team for ALS/MND

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. Travel grants provided by Novartis, Biogen Idec and Merck Serono to attend international neurology meetings.

    Editorial Boards:

    1. Editor in Chief Amyotrophic Lateral Sclerosis and Frontotemporal Dementia Editorial Board Journal of Neurology Neurosurgery & Psychiatry

    Patents:

    1. Patents Patent Title: Treatment of Central Nervous System Injury Inventors (RCSI): Orla Hardiman Jochen Prehn ; Matt Greenway Dairin Kieran Application No.: PCT/IE2006/000091 Country: International Status: Pending Patent Title: Treatment of Neurodegenerative Disease Inventors (RCSI): Orla Hardiman ;Matt Greenway Application No.: WO2005IE00131 Country: International Status: Pending Publication No: WO2006054277

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. The research leading to these results has received funding from the EuropeanCommunity's Seventh Framework Programme (FP7/2007-2013) under grant agreement n? [259867]. Health Research Board CSA2007/03 Research Motor Neuron ALSA

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the Department of Biology (N.M.B.), University of Pennsylvania, Philadelphia; and the Academic Unit of Neurology (O.H.), Trinity Biomedical Sciences Institute, Trinity College, Dublin, Ireland.
  1. Correspondence to Dr. Bonini: nbonini{at}sas.upenn.edu or Dr. Hardiman: oral{at}hardiman.net
View Full Text

Article usage

Article usage: December 2014 to December 2022

AbstractFullPdfSource
Dec 2014158029Highwire
Jan 20153932346Highwire
Feb 2015561415Highwire
Mar 201538510Highwire
Apr 20151943Highwire
May 20152222Highwire
Jun 20152632Highwire
Jul 20151543Highwire
Aug 20152166Highwire
Sep 20152723Highwire
Oct 20151454Highwire
Nov 2015945Highwire
Dec 20151131Highwire
Jan 20161630Highwire
Feb 20161422Highwire
Mar 20161313Highwire
Apr 20161311Highwire
May 20161100Highwire
Jun 2016802Highwire
Jul 20161301Highwire
Aug 20161033Highwire
Sep 20161112Highwire
Oct 20161531Highwire
Nov 20161811Highwire
Dec 2016700Highwire
Jan 20171711Highwire
Feb 20172210Highwire
Mar 2017901Highwire
Apr 20171504Highwire
May 20171403Highwire
Jun 2017601Highwire
Jul 2017400Highwire
Aug 2017900Highwire
Sep 2017600Highwire
Oct 2017300Highwire
Nov 2017800Highwire
Dec 2017900Highwire
Jan 20181411Highwire
Feb 20181101Highwire
Mar 20181300Highwire
Apr 20183200Highwire
May 20181111Highwire
Jun 20181211Highwire
Jul 20182400Highwire
Aug 20182001Highwire
Sep 20181000Highwire
Oct 2018900Highwire
Nov 20181900Highwire
Dec 20182800Highwire
Jan 2019800Highwire
Feb 2019511Highwire
Mar 20191400Highwire
Apr 20192610Highwire
May 20191100Highwire
Jun 2019900Highwire
Jul 2019500Highwire
Aug 20191000Highwire
Sep 2019631Highwire
Oct 20192111Highwire
Nov 20191811Highwire
Dec 2019800Highwire
Jan 2020400Highwire
Feb 20201100Highwire
Mar 2020600Highwire
Apr 2020623Highwire
May 2020900Highwire
Jun 2020400Highwire
Jul 2020711Highwire
Aug 2020511Highwire
Sep 2020820Highwire
Oct 2020100Highwire
Nov 20201210Highwire
Dec 2020511Highwire
Jan 2021600Highwire
Feb 20211600Highwire
Mar 20212353Highwire
Apr 20211210Highwire
May 20211000Highwire
Jun 20211110Highwire
Jul 2021800Highwire
Aug 20211100Highwire
Sep 2021711Highwire
Oct 2021810Highwire
Nov 20211000Highwire
Dec 20211322Highwire
Jan 2022500Highwire
Feb 20221500Highwire
Mar 2022601Highwire
Apr 20221111Highwire
May 20221100Highwire
Jun 2022600Highwire
Jul 2022602Highwire
Aug 2022400Highwire
Sep 2022200Highwire
Oct 2022600Highwire
Nov 20221011Highwire
Dec 2022800Highwire

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

Topics Discussed

Alert Me